Review Article
Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis
Table 1
Basic demographics and clinical characteristics of each included study.
| Authors | Sample size, | Follow-up, month | Age, year | EDSS | MS subtype, % | MS duration, year | Cell source | Transplantation way |
| Bonab et al. | 10 | 19 (13-26) | 33 (22-40) | 5.15 (3.5-6) | SPMS (80%) PPMS (20%) | 11.2 (3-21) | Bone marrow | Intrathecal injection |
| Karussis et al. | 15 | 6 | | 6.7 (4-8) | NA | 10.7 (5-15) | Bone marrow | Intrathecal and intravenous injection |
| Yamout et al. | 7 | 12 | 42 (34-49) | 6.5 (4.5-7.5) | SPMS (100%) | 19.9 (11-39) | Bone marrow | Intrathecal injection |
| Bonab et al. | 22 | 12 | 35.2 (23-50) | 6.2 (5.5-7) | SPMS (91%) PRMS (9%) | 8.68 (5-14) | Bone marrow | Intrathecal injection |
| Connick et al. | 10 | 12 | 48.8 (40–53) | 6.1 (5.5–6.5) | SPMS (100%) | 14.4 (5–26) | Bone marrow | Intravenous injection |
| Harris et al. | 6 | 88.8 (48-96) | 43 (28-64) | 7.3 (6.5-9) | SPMS (67%) PPMS (33%) | 17 (7-27) | Bone marrow | Intrathecal injection |
| Cohen et al. | 6 | 12 | | 6 (3–6.5) | SPMS (58%) RRMS (42%) | | Bone marrow | Intravenous injection |
| Fernández et al. | 19 | 12 | | | SPMS (100%) | | Adipose | Intravenous injection |
| Harris et al. | 20 | 12 | 49 (27-65) | 6.8 (3.5-8.5) | SPMS (80%) PPMS (20%) | 18.8 (10-32) | Bone marrow | Intrathecal injection |
|
|